BNP Paribas Financial Markets
ATNM icon

BNP Paribas Financial Markets’s Actinium Pharmaceuticals ATNM Stock Holding History

BNP Paribas Financial Markets’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$236 Hold
237
– – ﹤0.01% 5615
2025
Q4 		$322 Hold
237
– – ﹤0.01% 5520
2025
Q3 		$379 Sell
237
-1,150
-83% -$1.87K ﹤0.01% 5335
2025
Q2 		$1.94K Sell
1,387
-446
-24% -$667 ﹤0.01% 5060
2025
Q1 		$2.95K Sell
1,833
-3,911
-68% -$4.96K ﹤0.01% 4931
2024
Q4 		$7.24K Buy
+5,744
New +$8.91K ﹤0.01% 4889
2015
Q2 		– Sell
-37
Closed -$2.75K – 3546
2015
Q1 		$2.75K Buy
+37
New +$4.4K ﹤0.01% 3409
2014
Q4 		– Sell
-46
Closed -$9.15K – 2068
2014
Q3 		$9.15K Buy
+46
New +$9.12K ﹤0.01% 3630

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Financial Markets's ATNM Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 237 shares worth $236. The position accounts for ﹤0.01% of the portfolio, ranked #5615.

BNP Paribas Financial Markets first reported a position in ATNM in Q3 2014 and has held it in 8 quarters since. The position peaked at $9.15K in Q3 2014. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • BNP Paribas Financial Markets held 237 shares of Actinium Pharmaceuticals worth $236 as of Q1 2026.
  • BNP Paribas Financial Markets left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5615 holding.
  • BNP Paribas Financial Markets first reported a position in Actinium Pharmaceuticals in Q3 2014 and has held it in 8 quarters since.
  • BNP Paribas Financial Markets's Actinium Pharmaceuticals position peaked at $9.15K in Q3 2014.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.